This condition can lead to sustained and progressive increase in pulmonary vascular resistance, which eventually may result in right ventricle (RV) failure. Diagnosed late and untreated, this life-threatening condition has a poor prognosis. Treatment of the specific causes can improve the prognosis and assure therapeutic success. 1 The comprehensive clinical classification of PH according to the 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension, recognize five main groups of PH, pulmonary arterial hypertension (PAH) representing group I. This is characterized hemodynamically by the presence of pre-capillary PH (PAPm ≥25 mmHg, PAWP ≤15 mmHg) and pulmonary vascular resistance >3 Wood units.
Connective tissue diseases (CTD), as a distinctive group of disorders, lead to PAH, in addition to multiple complications. This specific entity is identified as subgroup 1.4.1 in the most recent clasification. 3 Systemic scleroderma (SSc) is associated with pre-capillary PH in about 5 to 12% of patients already diagnosed with connective tissue diseases. 6 In the group of autoimmune CTD, systemic scleroderma is characterized by progressive fibrosis of the skin and vasculopathy with multiple visceral damage, including the lungs. Scleroderma prevalence is low, but it has high morbidity and mortality.
Pulmonary hypertension associated with scleroderma (SSc-PAH) can often result in poor prognosis with increased mortality. Not only diffuse cutaneous, but also limited cutaneous forms of scleroderma are at risk for cardiac involvement and SSc-PAH.
Screening for the presence of scleroderma in PH diagnosed patients should be performed, as earlier diagnosis and treatment can result in a better prognosis. 8 
cASE PrESEntAtion
We present the case of a 50 year-old man, referred to a PH referral center presenting exertional dyspnea, fatigue, episodes of syncope and mild peripheral edema. Family history was negative for pulmonary or heart diseases with significance in the patient's present status. From previous medical records the patient had a 2-year history of PH diagnosis based on echocardiographic data (mean systolic pulmonary artery pressure of 78 mmHg).
The patient was also an ex-smoker, with previous moderate alcohol consumption.
On admission, physical examination revealed normal BMI: 20.7 kg/m 2 , afebrile status, apparently no respiratory or infectious diseases at the time of examination and no signs of any neurological disorder. Skin examination revealed areas of thick skin, almost impossible to fold, localized on both hands and also small areas on both forearms. Lymph node examination did not show any significant findings. Vital signs were within normal range: BP was 115/70 mm Hg, heart rate 116/min, peripheral oxygen saturation assessed by pulse oximetry 96% during rest, without oxygen supply. Cardiac auscultation revealed mitral systolic murmur, II/6 degree in intensity, which radiated posteriorly and to the left axilla. An increased enlarged liver (about 18 cm), slightly tender to palpation was noticed during abdominal examination.
Based on previous echocardiographic probability of pulmonary hypertension in a symptomatic patient with a clinical suspicion of PH, further investigations were scheduled in order to confirm and to identify the clinical classification of pulmonary hypertension.
Evaluation of severity and risk assessment of the patient was performed based on clinical parameters, routine and additional tests, imaging and hemodynamics. 3 Twelve-lead rest ECG detected sinus tachycardia (Figure 1 ) at an average heart rate of 112 bpm, right ventricular overload expressed by the presence of pulmonary P wave, right QRS axis deviation, qR aspect in V1, R wave in V2, right bundle branch block.
Routine blood tests revealed initially elevated gamma GT levels (183 U/l) which decreased under right heart failure treatment to 162 U/l; NT-pro BNP plasma levels 3,215.00 pg/ml.
Six-minute walk test (6MWT) confirmed dyspnea on exertion, with a decrease in peripheral oxygen saturation from 96% at rest to 85% and an increase in heart rate from 110 bpm to 120 bpm. A walk test on 220 meters was performed in 6 minutes, Borg scale 9 at the end of the 6MWT.
Transthoracic echocardiography showed dilated right heart cavities, hypokinetic right ventricle, right ventricular hypertrophy, minor mitral and pulmonary regurgitation, moderate to severe tricuspid regurgitation, dilated pulmonary artery (both trunk and main branches), with a mildly decreased ejection fraction (50%); a small to moderate pericardial effusion (PE) was also noticed.
Peripheral venous Doppler ultrasound examination was within the normal limits and respiratory functional test (spirometry) showed mild restrictive respiratory dysfunction.
Chest X-Ray revealed central pulmonary arterial dilatation; no right atrium or right ventricle enlargement was observed.
After classification as intermediate-to-high risk of PH, the evaluation continued with the right heart catheterization (RHC) as a definitive diagnosis tool for the identification of the more common clinical groups of PH group 2 (LHD) and group 3 (lung diseases), distinguishing group 4 (CTEPH) and state the diagnosis for further recognition of the different types in group 1 (PAH).
RHC confirmed the diagnosis of pre-capillary PAH with a mean pulmonary artery pressure of 36 mm Hg (69/22/36 mmHg) and an indexed pulmonary vascular resistance of 15.01 HRUI.
CT pulmonary angiography showed no evidence of pulmonary thromboembolism, but confirmed both right heart and pulmonary artery morphological changes.
Immune serology was tested for the accurate etiology of different forms with similar clinical manifestation of pulmonary arterial hypertension (group 1). The results showed positive IgE (559.4 UI/l), anti-nuclear antibodies (ANA), IgG cardiolipin antibodies (26.4 UGPL/ml), borderline increased of SCL-70 levels and increased levels of U3-RNP (anti-fibrillar) antibodies.
The first therapeutic decision, along with the initial approach that included general measures and supportive therapy (diuretics), was addressed to specific therapy for pulmonary arterial hypertension. Considering the fact that PAH was associated with limited cutaneous scleroderma, we decided to combine the specific therapies for both diseases, in the lowest doses resulting in a maximum effect. Therefore, the patient is currently under treatment with 10 mg methotrexate/week to improve prognosis and life expectancy. Follow-up of immunomodulatory and specific antifibrotic therapy for scleroderma diminished the skin lesion progression with good drug tolerance. The patient's clinical evolution in the following 6 months from the start of treatment will define the adjusting of methotrexate dose in the treatment of scleroderma.
According to current guidelines regarding the evaluation of severity and risk assessment in PAH, the patient was assessed at three months: no progression of symptoms or syncope, WHO functional class I/II, 6MWT: 580 m, Borg scale 2/3 (form 9), transthoracic echocardiography with a decrease of systolic pulmonary arterial pressure from 85 to 50 mmHg, with intermediate risk (RA area 25 cm 2 , minimal pericardial effusion and NT-proBP values of 2,123.00 pg/ml).
diScuSSion
Concerning the etiology of PAH, connective tissue disease was suspected based on the patient's history (smoking, alcohol consumption), clinical presentation (fatigue, dyspnea), clinical appearance (skin modifications) and pericardial effusion presence (transthoracic echocardiography, CT pulmonary angiography).
Data from specific literature infer that when compared to idiopathic PAH (IPAH), patients with SSc-PAH are more frequently females, older and present more advanced stages of illness.
Immune serology pointed initially to undifferentiated connective tissue disease or scleroderma on its onset, as SCL-70 and U3-RNP (anti-fibrillarin) antibodies were borderline at first dosage. Laboratory findings pointed also to high levels of IgE (559.4 UI/l), anti-nuclear antibodies (ANA) positive, Ig G cardiolipin antibodies (26.4 UGPL/ ml) positive. SCL-70 and U3-RNP (anti-fibrillarin) antibodies were elevated on repeated dosage, after six months.
The diagnosis of scleroderma was established using 2013 ACR/EULAR Classification Criteria for Scleroderma. Based on the findings above, the diagnosis score for the patient was 14 points (skin thickening of the fingers of both hands, extending proximally to the metacarpal joints -the most important and sufficient criterion, PAH present, borderline positive SCL-70 and increased anti-fibrillarin (U3-RNP) antibodies).
Skin modifications of the hands were the main criterion for scleroderma diagnosis. It is most likely that the connective tissue disease was diagnosed at its onset, as the specific antibodies have turned positive in a six months period. Other connective tissue diseases were discussed in the case of this patient, mainly systemic lupus erythematosus (SLE), rheumatoid arthritis and mixed connective tissue disease (MCTD). The differential diagnosis of scleroderma was finally made on immune serology basis, as ADNdc and Sm antibodies -specific for SLE and/or MCTD, cyclic citrullinated peptide (CCP) antibodies -specific for RA and U1-RNP antibodies -specific for MCTD were absent or negative.
The particularity of the case lies in the fact that the patient presented with symptoms of non-specific PH, mainly related to progressive right ventricular (RV) dysfunction, present since the onset of scleroderma. In the literature, 60% of SSc-related deaths are associated to the direct pulmonary involvement of SSc, determining interstitial lung disease and PH.
Furthermore, PH is more common in a subset of limited cutaneous sclerosis form (lcSSc) when compared to diffuse disease. A multidisciplinary approach including general practitioners, pneumologists, cardiologists and rheumatologists in the evaluation of PH in these patients is essential in order to refine the diagnosis and set out the treatment algorithm.
conSEnt
Written informed consent was obtained from the patient for the publication of this case report. A copy of the consent is available at request.
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